<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542617</url>
  </required_header>
  <id_info>
    <org_study_id>ORT-2559-03928</org_study_id>
    <nct_id>NCT03542617</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Intravenous Dexamethasone on Postoperative Pain After Primary Total Hip Arthroplasty</brief_title>
  <official_title>Effect of Preoperative Intravenous Dexamethasone on Postoperative Pain After Primary Total Hip Arthroplasty : A Prospective, Double-blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of preoperative intravenous Dexamethasone between 10 mg and 40 mg with
      placebo on Postoperative Pain After Primary Total Hip Arthroplasty
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It still unclear whether the effective dose preoperative intravenous dexamethasone on
      postoperative pain after Total Hip Arthroplasty. The research hypothesis is that the effect
      of 10 mg intravenous Dexamethasone in postoperative pain(5 metre walking at 24 hour) is not
      inferior to 40 mg intravenous Dexamethasone
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scales for pain during five-metre walking (0-100)</measure>
    <time_frame>at 24 hours postoperatively</time_frame>
    <description>Each pain outcome will be assessed using a visual analogue scale of 0-100 mm, in which 0 indicates no pain and 100 indicates the worst pain;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for pain during five-metre walking (0-100)</measure>
    <time_frame>Postoperative at 48,72 hours.</time_frame>
    <description>Each pain outcome will be assessed using a visual analogue scale of 0-100 mm, in which 0 indicates no pain and 100 indicates the worst pain;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for pain on 45 degree active hip flexion (0-100)</measure>
    <time_frame>Postoperative at 24,48,72 hours.</time_frame>
    <description>Each pain outcome will be assessed using a visual analogue scale of 0-100 mm, in which 0 indicates no pain and 100 indicates the worst pain;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for current pain at rest on supine position (0-100)</measure>
    <time_frame>Postoperative at 6,24,48,72 hours.</time_frame>
    <description>Each pain outcome will be assessed using a visual analogue scale of 0-100 mm, in which 0 indicates no pain and 100 indicates the worst pain;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for the maximal pain at rest over the last 24 hours and the minimal pain at rest over the last 24 hours (0-100)</measure>
    <time_frame>Postoperative at 0-24,24-48,48-72 hours.</time_frame>
    <description>Each pain outcome will be assessed using a visual analogue scale of 0-100 mm, in which 0 indicates no pain and 100 indicates the worst pain;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for nausea (0-100)</measure>
    <time_frame>Postoperative at 6,24,48,72 hours</time_frame>
    <description>This outcome will be assessed in a form of visual analogue scale of 0-100 mm, in which 0 indicates no nausea or vomiting and 100 indicates the worst nausea or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption (mg.)</measure>
    <time_frame>Postoperative at 0-24,24-48,48-72 hours</time_frame>
    <description>Opioid consumption (mg.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-emetic medicine consumption (mg.)</measure>
    <time_frame>Postoperative at 0-24,24-48,48-72 hours</time_frame>
    <description>Anti-emetic medicine consumption (mg.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complication</measure>
    <time_frame>Postoperative at Discharge, 2 weeks, 6 weeks, 12 weeks.</time_frame>
    <description>Wound complications (including periprosthetic joint infection and inadequate wound healing). Periprosthetic joint infection will be diagnosed using the criteria outlined by the Musculoskeletal Infection Society. Inadequate wound healing is defined as delayed wound healing or wound dehiscence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Localized Primary Osteoarthritis of Both Hips (Diagnosis)</condition>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>10 mg Dexamethasone</arm_group_label>
    <arm_group_label>40 mg Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Solution</intervention_name>
    <arm_group_label>Normal Saline Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Undergoing Elective, Primary, unilateral Total Hip arthroplasty

          -  American Society of Anesthesiology (ASA) physical class 1-3

          -  BMI &lt; 40 kg/m2

        Exclusion Criteria:

          -  History of previous musculoskeletal injury on the same hip

          -  History of prior surgery on the same unilateral hip

          -  History of adverse effects from medication utilized in this study

          -  Contraindication to spinal anesthesia

          -  History of psychiatric disorders or cognitive impairment

          -  Contraindication to Corticosteroid

          -  Poorly controlled Diabetes mellitus

          -  History of ischemic heart disease or peripheral arterial disease or cerebrovascular
             disease

          -  Hepatic insufficiency (Child-Pugh score &gt; 5)

          -  Renal insufficiency (Creatinine clearance &lt; 30 mL/min)

          -  History of cataract or glaucoma or ocular hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vutinan Manassoontornvuti, MD</last_name>
    <phone>+66909712741</phone>
    <email>m.vutinan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitchanant Kitcharanant, MD</last_name>
    <phone>+66871071133</phone>
    <email>nk_win@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Orthopedics, Chiang Mai University</name>
      <address>
        <city>ChiangMai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitchanant Kitcharanant</last_name>
      <phone>+66871071133</phone>
      <email>nk_win@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Nitchanant Kitcharanant</investigator_full_name>
    <investigator_title>Effect of Preoperative Intravenous Dexamethasone on Postoperative Pain After Primary Total Hip Arthroplasty : A prospective, double-blind, randomized controlled trial</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

